Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line

Figure 6 Expressions of EGFR, Bcl-2, Bcl-xl, Bax, Bak and VEGF mRNA in BxPC-3 cells treated with different concentrations (μmol/L) of erlotinib for 48 h and xenograft tissues were detected by RT-PCR. A: Effects of erlotinib on the expressions of EGFR, apoptosis-associated factors and VEGF. Lane M: DNA marker; Lane C: Control; other lanes: Different concentrations of erlotinib. B: Effects of erlotinib (100 mg/kg daily) on expression of VEGF in tumor tissues. Lane M: DNA marker; Lane 1, 2: Control group; Lane 3, 4: Treatment group. RT-PCR for GAPDH was performed in parallel and showed an equal amount of total RNA in the sample.